Pfizer has reported that the patients treated with Toviaz (fesoterodine fumarate) 8mg extended release tablets had greater and statistically reductions in urge urinary incontinence episodes at week 12 compared with Detrol LA (tolterodine tartrate extended release capsules) in a placebo-controlled randomised clinical trial.
The primary endpoint of the study was reductions in urge urinary incontinence episodes. The new study, published today in the January issue of BJU International, is the first head-to-head superiority trial specifically designed to compare the two medications.
Reportedly, with prespecified secondary endpoints, patients treated with Toviaz 8mg had a greater increase in the average volume of urine voided per micturition from baseline to week 12 compared with those who received Detrol LA. The differences between Toviaz 8mg and Detrol LA in urinary frequency and urgency episodes were not statistically significant.
Sender Herschorn, lead author of Sunnybrook Health Sciences Centre, Toronto, said: “This is the first clinical trial that has been designed to assess the superiority of an antimuscarinic agent for the treatment of overactive bladder. This new data provides important information to physicians making treatment decisions for patients with overactive bladder since it compares two available medicines. This study showed that Toviaz 8mg was more efficacious than Detrol LA in treating urge urinary incontinence.”